Childhood interstitial lung diseases in immunocompetent children in Australia and New Zealand: a decade’s experience
| Autor: | Julian Vyas, Sean Beggs, Adam Jaffe, Joanne Harrison, André Schultz, Jill Lipsett, Bruce Bennetts, Amy Phu, Nitin Kapur, Lawrence M. Nogee, Yvonne Zurynski, Roxanne Strachan, Sadasivam Suresh, Hiran Selvadurai, Neil J Hime, Vishal Saddi, Stephanie Sherrard |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Pediatrics
medicine.medical_specialty Adolescent Prevalence lcsh:Medicine Interstitial lung disease chILD syndrome 03 medical and health sciences 0302 clinical medicine 030225 pediatrics medicine Humans Pharmacology (medical) Child Genetics (clinical) Pulmonologists Retrospective Studies Lung business.industry Research Data Collection Mortality rate lcsh:R Australia Infant General Medicine CHILD syndrome medicine.disease Clinical trial medicine.anatomical_structure 030228 respiratory system Child Preschool Population study Lung Diseases Interstitial business Immunocompetence New Zealand |
| Zdroj: | Orphanet Journal of Rare Diseases, Vol 12, Iss 1, Pp 1-9 (2017) Orphanet Journal of Rare Diseases |
| ISSN: | 1750-1172 |
| DOI: | 10.1186/s13023-017-0637-x |
| Popis: | Background Childhood interstitial lung disease (chILD) represents a rare heterogeneous group of respiratory disorders. In the absence of randomized controlled clinical trials, global collaborations have utilized case series with an aim to standardising approaches to diagnosis and management. Australasian data are lacking. The aim of this study was to calculate prevalence and report the experience of chILD in Australasia over a decade. Methods Paediatric pulmonologists in Australia and New Zealand involved in the care of patients aged 0–18 years with chILD completed a questionnaire on demographics, clinical features and outcomes, over a 10 year period. These data, together with data from the 2 reference genetics laboratories, were used to calculate prevalence. Results One hundred fifteen cases were identified equating to a period prevalence (range) of 1.5 (0.8–2.1) cases/million for children aged 0–18years. Clinical data were provided on 106 patients: the |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|